Retrophin to Present at Upcoming Investor Conferences
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Retrophin has announced its participation in two upcoming virtual investor conferences: the Jefferies 2020 Virtual London Healthcare Conference on November 18, 2020, at 6:45 p.m. GMT, and the 2020 Evercore ISI Virtual HealthCONx Conference on December 1, 2020, at 1:25 p.m. ET. Live webcasts and archived replays of these events will be available on the company's investor relations website for 30 days. Retrophin specializes in developing therapies for rare diseases, with a focus on conditions such as focal segmental glomerulosclerosis and IgA nephropathy.
Details
News Market Reaction – RTRX
The recorded move for RTRX in the trading session of this news was -1.96%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN DIEGO, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Company management will present at the following upcoming virtual investor conferences in November and December:
Jefferies 2020 Virtual London Healthcare Conference
Date: Wednesday, November 18, 2020
Time: 6:45 p.m. GMT (1:45 p.m. ET)
2020 Evercore ISI Virtual HealthCONx Conference
Date: Tuesday, December 1, 2020
Time: 1:25 p.m. ET
Live webcasts will be available at http://ir.retrophin.com/events and archived replays will be accessible for up to 30 days.
About Retrophin
Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life-changing therapies to people living with rare disease. The Company’s approach centers on its pipeline featuring sparsentan, a product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), rare disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease. Research in additional rare diseases is also underway, including partnerships with leaders in patient advocacy and government research to identify potential therapeutics for NGLY1 deficiency and Alagille syndrome, conditions with no approved treatment options. Retrophin’s R&D efforts are supported by revenues from the Company’s commercial products Chenodal®, Cholbam®, Thiola® and Thiola EC®.
Contact:
Chris Cline, CFA
Senior Vice President, Investor Relations & Corporate Communications
888-969-7879
IR@retrophin.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.